Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Replimune r&d expenses
Research and development expenses are spending on new products and technology.
Replimune's R&D Expenses for the twelve months ending Sep 30, 2026 was $189.11M, down 13.1% year over year. For fiscal 2026 it was $221.18M, up 16.8% from the year before. The highest annual figure on record is $221.18M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $221.18M | +16.8% |
| FY2025 | Mar 31, 2025 | $189.45M | +8.3% |
| FY2024 | Mar 31, 2024 | $174.96M | +38.3% |
| FY2023 | Mar 31, 2023 | $126.53M | +59.1% |
| FY2022 | Mar 31, 2022 | $79.55M | +40.2% |
| FY2021 | Mar 31, 2021 | $56.75M | +46.4% |
| FY2020 | Mar 31, 2020 | $38.76M | +74.8% |
| FY2019 | Mar 31, 2019 | $22.17M | +64.1% |
| FY2018 | Mar 31, 2018 | $13.52M | +94.9% |
| FY2017 | Mar 31, 2017 | $6.94M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $34.37M | -40.6% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $49.28M | -14.8% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $52.32M | -3.1% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $53.14M | +10.7% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $57.88M | +33.2% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $57.84M | +34.6% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $53.98M | +26.8% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $48.00M | +12.0% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $43.45M | -11.5% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $42.97M | +6.3% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $42.58M | +12.2% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $42.85M | +41.6% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $49.10M | +70.3% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $40.44M | +37.2% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $37.95M | +74.6% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $30.26M | +56.4% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $28.83M | +44.9% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $29.48M | +58.9% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $21.74M | +34.0% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $19.35M | +35.1% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $19.90M | +41.7% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $18.55M | +52.6% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $16.23M | +45.0% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $14.32M | +19.9% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $14.05M | +72.0% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $12.16M | +63.0% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $11.19M | +106.7% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $11.95M | +52.1% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $8.17M | +64.6% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $7.46M | +89.5% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $5.41M | +20.2% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $7.86M | +119.9% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $4.96M | +57.6% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $3.94M | +71.8% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $4.50M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $3.57M | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $3.15M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $2.29M | – |
See a number that looks wrong?